Program
EGFR Mutant-specific Inhibitor DZD6008
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Dizal Pharmaceuticals.
Furthest: phase 2, since Jul 10, 20253 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dizal Pharmaceuticals | 33 open or running | phase 2since Jul 10, 2025 | Dec 23, 2024 | Sep 2027phase 1 · NCT06905197 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06813365 · 300 planned · China
- Mar 25, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06905197 · 140 planned · United States, Australia
- Jul 10, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07079475 · 220 planned · China
Ahead
- Sep 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06905197
- Oct 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06813365
- Jun 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07079475
TargetBeta
EGFR →read by rule
“An orally available, blood-brain-barrier (BBB) penetrant, mutant-specific inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR), ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07079475Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2028 | 220 |
| NCT06905197Carcinoma, Non-Small-Cell Lung · United States, Australia | 1 | Recruiting | Sep 2027 | 140 |
| NCT06813365Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Oct 30, 2027 | 300 |
How it is read
Names in the registry
- “DZD6008”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.